Skip to content

Photoprovocation Testing in Subjects With Cutaneous Lupus

Photoprovocation Testing in Subjects With Cutaneous Lupus

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01516788
Enrollment
19
Registered
2012-01-25
Start date
2011-12-31
Completion date
2018-07-02
Last updated
2021-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lupus Erythematosus, Photosensitivity Conditions

Brief summary

Photosensitivity is well documented among lupus patients and is one of the diagnostic criteria for systemic lupus erythematosus (SLE). Photosensitivity is highly prevalent in lupus and has a wide range of clinical presentations. However, photosensitivity is a poorly defined in lupus and its pathogenesis is not well understood. The purpose of this study is to characterize the early clinical and histopathological changes in lupus skin that occur as a response to ultraviolet light.

Interventions

OTHERPhototesting

Single MED dose on Day 2

Sponsors

University of Pennsylvania
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Participants who have a diagnosis of CLE based on either the Gilliam classification of DLE and SCLE, or SLE based on the American College of Rheumatology criteria.

Exclusion criteria

1. Participants who do not meet criteria for either CLE or SLE. 2. Participants with a diagnosis of Erythropoietic Protoporphyria and Solar Urticaria, or another photodermatoses other than Polymorphous light eruption. 3. Participants who are not yet 18 years old or who are not capable of giving written informed consent prior to enrolling in the study. 4. Participants who have undergone any recent phototesting, or phototherapy exposure, or those who are suspected of having a drug-induced photosensitivity. 5. Female participants who are pregnant or breastfeeding will be excluded from the study. This will be determined by patient self-reporting.

Design outcomes

Primary

MeasureTime frame
The change from baseline of the neutrophil and inflammasome response to ultraviolet radiation at 24 hours.24 hours and 48 hours

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026